ESMO Consensus Guidelines for management of patients with colon and rectal cancer. A personalized approach to clinical decision makingHans‐Joachim Schmoll, Andrés Cervantes, Eric Van Cutsem et al.|Annals of Oncology|2012Cited by 1.5k
Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trialEdward S. Kim, Jean‐Yves Douillard, Mei‐Lin Liao et al.|The Lancet|2008Cited by 1.2k
Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trialMartin Reck, Silvia Novello, R. Kaiser et al.|The Lancet Oncology|2014Cited by 948
Pan-Asian adapted ESMO consensus guidelines for the management of patients with metastatic colorectal cancer: a JSMO–ESMO initiative endorsed by CSCO, KACO, MOS, SSO and TOSTakayuki Yoshino, Jean‐Yves Douillard, Dirk Arnold et al.|Annals of Oncology|2017Cited by 591
Definitive chemoradiotherapy with FOLFOX versus fluorouracil and cisplatin in patients with oesophageal cancer (PRODIGE5/ACCORD17): final results of a randomised, phase 2/3 trialThierry Conroy, Antoine Adenis, Marie‐Pierre Galais et al.|The Lancet Oncology|2014Cited by 446